Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bang

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Clinical and Vaccine Immunology : CVI|May 1, 2015
Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T CellsNicole Lenz, Tobias Schindler, Benjamin M Kagina, et al.
Vaccine|March 16, 2010
Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteersJaap T van Dissel, Sandra M Arend, Corine Prins, et al.
Trials|January 12, 2018
A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic areaJemal Hussein, Martha Zewdie, Lawrence Yamuah, et al.
Vaccine|November 22, 2016
H1:IC31 vaccination is safe and induces long-lived TNF-α<sup>+</sup>IL-2<sup>+</sup>CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trialHelen Mearns, Hennie D Geldenhuys, Benjamin M Kagina, et al.
Vaccine|June 27, 2021
Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccineSylvester Dassah, Bright Adu, Sodiomon B Sirima, et al.
Vaccine|August 2, 2016
A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African childrenSodiomon B Sirima, Benjamin Mordmüller, Paul Milligan, et al.
Vaccine|January 25, 2011
Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infectionJaap T van Dissel, Darius Soonawala, Simone A Joosten, et al.
The Lancet. Infectious Diseases|August 17, 2019
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trialSonya Abraham, Helene B Juel, Peter Bang, et al.
Plos One|December 10, 2014
Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trialKlaus Reither, Lynn Katsoulis, Trevor Beattie, et al.
The Journal of Clinical Endocrinology and Metabolism|July 2, 2010
Impact of heterozygosity for acid-labile subunit (IGFALS) gene mutations on stature: results from the international acid-labile subunit consortiumOlga V Fofanova-Gambetti, Vivian Hwa, Jan M Wit, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Clinical and Vaccine Immunology : CVI|May 1, 2015
Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T CellsNicole Lenz, Tobias Schindler, Benjamin M Kagina, et al.
Vaccine|March 16, 2010
Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteersJaap T van Dissel, Sandra M Arend, Corine Prins, et al.
Trials|January 12, 2018
A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic areaJemal Hussein, Martha Zewdie, Lawrence Yamuah, et al.
Vaccine|November 22, 2016
H1:IC31 vaccination is safe and induces long-lived TNF-α<sup>+</sup>IL-2<sup>+</sup>CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trialHelen Mearns, Hennie D Geldenhuys, Benjamin M Kagina, et al.
Vaccine|June 27, 2021
Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccineSylvester Dassah, Bright Adu, Sodiomon B Sirima, et al.
Vaccine|August 2, 2016
A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African childrenSodiomon B Sirima, Benjamin Mordmüller, Paul Milligan, et al.
Vaccine|January 25, 2011
Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infectionJaap T van Dissel, Darius Soonawala, Simone A Joosten, et al.
The Lancet. Infectious Diseases|August 17, 2019
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trialSonya Abraham, Helene B Juel, Peter Bang, et al.
Plos One|December 10, 2014
Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trialKlaus Reither, Lynn Katsoulis, Trevor Beattie, et al.
The Journal of Clinical Endocrinology and Metabolism|July 2, 2010
Impact of heterozygosity for acid-labile subunit (IGFALS) gene mutations on stature: results from the international acid-labile subunit consortiumOlga V Fofanova-Gambetti, Vivian Hwa, Jan M Wit, et al.
Pageof 7